These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 25459391)
21. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258 [TBL] [Abstract][Full Text] [Related]
22. Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). De Santis M; Wiechno PJ; Bellmunt J; Lucas C; Su WC; Albiges L; Lin CC; Senkus-Konefka E; Flechon A; Mourey L; Necchi A; Loidl WC; Retz MM; Vaissière N; Culine S Ann Oncol; 2016 Mar; 27(3):449-54. PubMed ID: 26673352 [TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149 [TBL] [Abstract][Full Text] [Related]
24. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503 [TBL] [Abstract][Full Text] [Related]
25. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259 [TBL] [Abstract][Full Text] [Related]
26. Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond. Cheng T Curr Opin Support Palliat Care; 2008 Sep; 2(3):153-60. PubMed ID: 18685414 [TBL] [Abstract][Full Text] [Related]
27. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452 [TBL] [Abstract][Full Text] [Related]
28. A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. Jones R; Crabb S; Chester J; Elliott T; Huddart R; Birtle A; Evans L; Lester J; Jagdev S; Casbard A; Huang C; Madden TA; Griffiths G BJU Int; 2020 Aug; 126(2):292-299. PubMed ID: 32336008 [TBL] [Abstract][Full Text] [Related]
29. Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. Orlando L; Giotta F; Lorusso V; De Vita F; Filippelli G; Maiello E; Riccardi F; Pappagallo GL; Fedele P; Gebbia N; Verderame F; Barni S; Blasi L; Pisconti S; Colucci G; Cinieri S Future Oncol; 2014 Apr; 10(5):725-33. PubMed ID: 24799054 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Soularue É; Cohen R; Tournigand C; Zaanan A; Louvet C; Bachet JB; Hentic O; Samalin E; Chibaudel B; de Gramont A; André T; Bull Cancer; 2015 Apr; 102(4):324-31. PubMed ID: 25744576 [TBL] [Abstract][Full Text] [Related]
31. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients. Zhu B; Wu JR; Zhou XP Medicine (Baltimore); 2015 Aug; 94(34):e1428. PubMed ID: 26313797 [TBL] [Abstract][Full Text] [Related]
32. Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine. Wezel F; Erben P; Gaiser T; Budjan J; von Hardenberg J; Michel MS; Bolenz C Urol Int; 2018; 100(1):122-125. PubMed ID: 26780095 [TBL] [Abstract][Full Text] [Related]
33. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Sledge GW Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403 [TBL] [Abstract][Full Text] [Related]
34. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Mazzanti P; Massacesi C; Rocchi MB; Mattioli R; Lippe P; Trivisonne R; Buzzi F; De Signoribus G; Tuveri G; Rossi G; Di Lullo L; Sturba F; Morale D; Catanzani S; Pilone A; Bonsignori M; Battelli T Lung Cancer; 2003 Jul; 41(1):81-9. PubMed ID: 12826316 [TBL] [Abstract][Full Text] [Related]
35. Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum. Park JH; Lee JL Cancer Chemother Pharmacol; 2015 Feb; 75(2):247-54. PubMed ID: 25428517 [TBL] [Abstract][Full Text] [Related]
36. Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Conlin AK; Seidman AD; Bach A; Lake D; Dickler M; D'Andrea G; Traina T; Danso M; Brufsky AM; Saleh M; Clawson A; Hudis CA Clin Breast Cancer; 2010 Aug; 10(4):281-7. PubMed ID: 20705560 [TBL] [Abstract][Full Text] [Related]
37. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial. García-Donas J; Font A; Pérez-Valderrama B; Virizuela JA; Climent MÁ; Hernando-Polo S; Arranz JÁ; Del Mar Llorente M; Lainez N; Villa-Guzmán JC; Mellado B; González Del Alba A; Castellano D; Gallardo E; Anido U; García Del Muro X; Domènech M; Puente J; Morales-Barrera R; Pérez-Gracia JL; Bellmunt J Lancet Oncol; 2017 May; 18(5):672-681a. PubMed ID: 28389316 [TBL] [Abstract][Full Text] [Related]
38. Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. O'Shaughnessy JA; Vukelja S; Marsland T; Kimmel G; Ratnam S; Pippen JE Clin Breast Cancer; 2004 Jun; 5(2):142-7. PubMed ID: 15245619 [TBL] [Abstract][Full Text] [Related]
39. Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group. Boukovinas I; Androulakis N; Vamvakas L; Papakotoulas P; Ziras N; Polyzos A; Kalykaki A; Kotsakis A; Xenidis N; Gioulmbasanis I; Mavroudis D; Georgoulias V Ann Oncol; 2006 Nov; 17(11):1687-92. PubMed ID: 16968872 [TBL] [Abstract][Full Text] [Related]
40. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. Butts CA; Bodkin D; Middleman EL; Englund CW; Ellison D; Alam Y; Kreisman H; Graze P; Maher J; Ross HJ; Ellis PM; McNulty W; Kaplan E; Pautret V; Weber MR; Shepherd FA J Clin Oncol; 2007 Dec; 25(36):5777-84. PubMed ID: 18089875 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]